The PyroGene recombinant Factor C assay (rFC) assay represents a reliable, sustainable alternative to LAL.
Factor C is the first component in the horseshoe crab clotting cascade activated by endotoxin. Recombinant Factor C (rFC) is activated by endotoxin binding, and the active enzyme then cleaves a synthetic substrate, resulting in the generation of a fluorogenic compound.
The reaction is run in a 96-well microplate and is measured at time zero and after a one-hour incubation in a fluorescent microplate reader using 380 nm excitation/440 nm emission wavelengths. The log net fluorescence is proportional to the log endotoxin concentration and is linear in the 0.01-10 EU/mL range.
Benefits include: endotoxin specific, recombinant technology eliminates false-positive glucan reactions; predictable, reliable lot-to-lot assay performance; sustainable resource - no animal utilisation; endpoint fluorescent assay, comparable to other quantitative LAL methods; and 510 (K) submissions have been approved by the FDA using PyroGene rFC Assay as a final release test.
Phone: 1300 657508
ALA Scientific Instruments RuFus cell unroofing system for plasma membrane isolation
ALA Scientific Instruments offers RuFus, a complete and user-friendly system for performing cell...
Lonza plateable mouse hepatocytes
Lonza provides plateable mouse hepatocytes from the four most common research mouse strains,...
PEPperPRINT cLIFT peptide microarray platform
At the core of the technology is a laser-based transfer process that is designed to deposit amino...